Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. CASCADE (SGN33A-005)

    ... 33A) combined with either azacitidine or decitabine extends overall survival longer than placebo combined with either azacitidine or decitabine. Status:  ...

    Clinical Trial last updated 06/19/2017 - 2:43pm.

  2. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up

    ... agents (HMA), such as 5- azacitidine or decitabine , are currently used to treat patients with myelodysplastic ...

    Research Article last updated 05/26/2015 - 12:53pm.

  3. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

    ... blasts after failure of azacitidine or decitabine treatment. METHODS: We did this randomised controlled ...

    Research Article last updated 06/07/2016 - 11:10am.

  4. Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes.

    ...

    Research Article last updated 06/28/2013 - 1:49pm.

  5. Shirley O’Brien’s Remarkable Response in a Clinical Trial

    ... blood cell counts. My treatment at the beginning was decitabine (Dacogen®) for 5 days every 28 days. Then after seven months, I ...

    Patient Chronicle last updated 07/19/2017 - 8:12am.

  6. Recent developments in myelodysplastic syndromes

    ... (US). US regulatory approval of azacitidine , decitabine , and lenalidomide between 2004 and 2006 seemed to herald ...

    Research Article last updated 04/29/2016 - 11:34am.

  7. Myelodysplastic syndromes: Contemporary review and how we treat

    ... the hypomethylating agents (HMA) azacitidine and decitabine and lenalidomide for MDS with isolated del(5q). To date, ...

    Research Article last updated 04/29/2016 - 1:05pm.

  8. Personalized medicine for MDS

    ... agents, such as azacitidine and decitabine , are standard care for older patients with higher-risk MDS who ...

    Research Review last updated 05/02/2016 - 9:44am.

  9. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

    ... hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered ... syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, ...

    Research Article last updated 11/19/2015 - 8:32am.

  10. Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine.

    ... This retrospective analysis evaluated response to decitabine using updated IWG criteria in patients pooled from 2 decitabine trials. PATIENTS AND METHODS: Outcomes for patients with ...

    Research Article last updated 06/28/2013 - 1:20pm.